News

XTL Biopharmaceuticals has reported a net loss of $9.25m, or $0.03 per ordinary share, for the year ended December 31, 2008, compared to a net loss of $24.94m,

Mr McCutcheon joins Ventus Medical from Emphasys Medical where he was president and CEO for the past seven years. Previously, Mr McCutcheon was head of sales and marketing

Celsion, a biotechnology company, has reported promising clinical results from its Phase I trial evaluating ThermoDox for the treatment of recurrent chest wall breast cancer. The Phase I

Orthocon’s $25 million financing was co-led by ProQuest Investments and Canaan Partners. The round has also included significant participation from Orthocon’s existing stockholder BB Biotech Ventures. Joyce Tsang,

Pursuant to the settlement, Mylan will have the right to market desloratadine tablets, 5mg, in the US on July 1, 2012, or earlier in certain circumstances, provided that

The grant, which will total $265,000 each year, for the next three years, will be used solely to support and conduct basic and clinical research relating to kidney

Under the terms of the agreement, Cardiovascular Systems will distribute Invatec’s FDA-cleared percutaneous transluminal angioplasty (PTA) balloon catheter product line. The agreement is believed to expand Invatec’s US

Theravance, a biopharmaceutical company, has announced that the FDA has accepted for filing the new drug application for telavancin, a novel, bactericidal, once-daily injectable investigational antibiotic, for the

Through this acquisition, Sunwin expects to convert Qufu Shengren’s pharmaceutical production facilities to the production of high grade stevia in approximately three months saving substantial construction time for